文献速递心脑血管急症

利伐沙班联合或不联合阿司匹林治疗稳定性外周或颈动脉疾病:一项国际、随机、双盲、安慰剂对照试验

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Lancet · 2017-11-10
一句话结论外周动脉疾病患者中,利伐沙班2.5 mg每日两次联合阿司匹林100 mg每日一次较单用阿司匹林降低心血管死亡、心梗或卒中(HR 0.72)及主要肢体不良事件(HR 0.54),但增加大出血(HR 1.61),致命或关键器官出血未增加。

该研究为多中心、双盲、随机、安慰剂对照试验,纳入7470例有下肢外周动脉疾病、颈动脉疾病或冠状动脉疾病伴踝臂指数<0.90的患者,随机接受利伐沙班2.5 mg每日两次联合阿司匹林100 mg每日一次、利伐沙班5 mg每日两次或阿司匹林100 mg每日一次。中位治疗21个月,联合治疗组较单用阿司匹林显著降低心血管死亡、心梗或卒中(5% vs 7%,HR 0.72,95%CI 0.57-0.90,p=0.0047)及主要肢体不良事件包括大截肢(1% vs 2%,HR 0.54,95%CI 0.35-0.82,p=0.0037),但大出血增加(3% vs 2%,HR 1.61,95%CI 1.12-2.31,p=0.0089),主要为消化道出血。利伐沙班5 mg每日两次未显著降低主要复合终点(HR 0.86,95%CI 0.69-1.08,p=0.19),但降低主要肢体不良事件(HR 0.67,95%CI 0.45-1.00,p=0.05),且大出血增加(HR 1.68,95%CI 1.17-2.40,p=0.0043)。

要点

  • 联合治疗组较单用阿司匹林显著降低心血管死亡、心梗或卒中(5% vs 7%,HR 0.72,95%CI 0.57-0.90,p=0.0047)及主要肢体不良事件包括大截肢(1% vs 2%,HR 0.54,95%CI 0.35-0.82,p=0.0037)。
  • 联合治疗组大出血较单用阿司匹林增加(3% vs 2%,HR 1.61,95%CI 1.12-2.31,p=0.0089),主要为消化道出血;致命或关键器官出血未增加。
  • 利伐沙班5 mg每日两次较单用阿司匹林未显著降低主要复合终点(6% vs 7%,HR 0.86,95%CI 0.69-1.08,p=0.19),但降低主要肢体不良事件(2% vs 2%,HR 0.67,95%CI 0.45-1.00,p=0.05),且大出血增加(3% vs 2%,HR 1.68,95%CI 1.17-2.40,p=0.0043)。
  • 中位治疗21个月,该联合方案在外周动脉疾病患者中降低主要心血管和肢体事件,但需权衡出血风险。

适用人群与场景

  • 有下肢外周动脉疾病史(既往外周旁路手术或血管成形术、肢体或足部截肢、间歇性跛行且有外周动脉疾病客观证据)、颈动脉疾病史(既往颈动脉血运重建或无症状颈动脉狭窄至少50%)或冠状动脉疾病伴踝臂指数<0.90的患者。

诊断标准与关键阈值

  • 无症状颈动脉狭窄至少50%为颈动脉疾病入选标准之一。
  • 冠状动脉疾病伴踝臂指数<0.90为冠状动脉疾病入选标准之一。

处置流程与药物剂量

  • 经30天导入期后,按1:1:1随机接受口服利伐沙班2.5 mg每日两次联合阿司匹林100 mg每日一次、利伐沙班5 mg每日两次(加阿司匹林安慰剂每日一次)或阿司匹林100 mg每日一次(加利伐沙班安慰剂每日两次)。
  • 中位治疗持续时间为21个月。

研究设计与关键结果

  • 多中心、双盲、随机、安慰剂对照试验,在六大洲33个国家的602家医院、诊所或社区诊所招募,最终从558个中心纳入7470例外周动脉疾病患者;2013年3月12日至2016年5月10日入组。
  • 联合治疗组 vs 阿司匹林单药组:心血管死亡、心梗或卒中复合终点126/2492(5%)vs 174/2504(7%),HR 0.72,95%CI 0.57-0.90,p=0.0047;主要肢体不良事件包括大截肢32/2492(1%)vs 60/2504(2%),HR 0.54,95%CI 0.35-0.82,p=0.0037。
  • 利伐沙班5 mg每日两次组 vs 阿司匹林单药组:主要复合终点149/2474(6%)vs 174/2504(7%),HR 0.86,95%CI 0.69-1.08,p=0.19;主要肢体不良事件包括大截肢40/2474(2%)vs 60/2504(2%),HR 0.67,95%CI 0.45-1.00,p=0.05。
  • 联合治疗组 vs 阿司匹林单药组:大出血77/2492(3%)vs 48/2504(2%),HR 1.61,95%CI 1.12-2.31,p=0.0089,主要为消化道出血;致命或关键器官出血未增加。
  • 利伐沙班5 mg每日两次组 vs 阿司匹林单药组:大出血79/2474(3%)vs 48/2504(2%),HR 1.68,95%CI 1.17-2.40,p=0.0043。
  • 中位治疗持续时间21个月。

证据类型、等级与局限

  • 研究类型:多中心、双盲、随机、安慰剂对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,低剂量利伐沙班每日两次联合阿司匹林每日一次较单用阿司匹林降低主要心血管和肢体不良事件,虽增加大出血但未增加致命或关键器官出血,该联合治疗代表外周动脉疾病管理的重要进展。
  • 作者指出,利伐沙班单用较阿司匹林单用未显著降低主要心血管不良事件,但降低主要肢体不良事件并增加大出血。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these complications.

METHODS: This was a multicentre, double-blind, randomised placebo-controlled trial for which patients were recruited at 602 hospitals, clinics, or community practices from 33 countries across six continents. Eligible patients had a history of peripheral artery disease of the lower extremities (previous peripheral bypass surgery or angioplasty, limb or foot amputation, intermittent claudication with objective evidence of peripheral artery disease), of the carotid arteries (previous carotid artery revascularisation or asymptomatic carotid artery stenosis of at least 50%), or coronary artery disease with an ankle-brachial index of less than 0·90. After a 30-day run-in period, patients were randomly assigned (1:1:1) to receive oral rivaroxaban (2·5 mg twice a day) plus aspirin (100 mg once a day), rivaroxaban twice a day (5 mg with aspirin placebo once a day), or to aspirin once a day (100 mg and rivaroxaban placebo twice a day). Randomisation was computer generated. Each treatment group was double dummy, and the patient, investigators, and central study staff were masked to treatment allocation. The primary outcome was cardiovascular death, myocardial infarction or stroke; the primary peripheral artery disease outcome was major adverse limb events including major amputation. This trial is registered with ClinicalTrials.gov, number NCT01776424, and is closed to new participants.

FINDINGS: Between March 12, 2013, and May 10, 2016, we enrolled 7470 patients with peripheral artery disease from 558 centres. The combination of rivaroxaban plus aspirin compared with aspirin alone reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke (126 [5%] of 2492 vs 174 [7%] of 2504; hazard ratio [HR] 0·72, 95% CI 0·57-0·90, p=0·0047), and major adverse limb events including major amputation (32 [1%] vs 60 [2%]; HR 0·54 95% CI 0·35-0·82, p=0·0037). Rivaroxaban 5 mg twice a day compared with aspirin alone did not significantly reduce the composite endpoint (149 [6%] of 2474 vs 174 [7%] of 2504; HR 0·86, 95% CI 0·69-1·08, p=0·19), but reduced major adverse limb events including major amputation (40 [2%] vs 60 [2%]; HR 0·67, 95% CI 0·45-1·00, p=0·05). The median duration of treatment was 21 months. The use of the rivaroxaban plus aspirin combination increased major bleeding compared with the aspirin alone group (77 [3%] of 2492 vs 48 [2%] of 2504; HR 1·61, 95% CI 1·12-2·31, p=0·0089), which was mainly gastrointestinal. Similarly, major bleeding occurred in 79 (3%) of 2474 patients with rivaroxaban 5 mg, and in 48 (2%) of 2504 in the aspirin alone group (HR 1·68, 95% CI 1·17-2·40; p=0·0043).

INTERPRETATION: Low-dose rivaroxaban taken twice a day plus aspirin once a day reduced major adverse cardiovascular and limb events when compared with aspirin alone. Although major bleeding was increased, fatal or critical organ bleeding was not. This combination therapy represents an important advance in the management of patients with peripheral artery disease. Rivaroxaban alone did not significantly reduce major adverse cardiovascular events compared with asprin alone, but reduced major adverse limb events and increased major bleeding.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017. PMID: 29132880. doi:10.1016/S0140-6736(17)32409-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。